About Plex Pharmaceuticals
Plex Pharmaceuticals is a company based in San Diego (United States) founded in 2009 was acquired by Collidion in August 2017. Plex Pharmaceuticals offers products and services including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors. Plex Pharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Plex Pharmaceuticals, Incorporated
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Plex Pharmaceuticals
Plex Pharmaceuticals offers a comprehensive portfolio of products and services, including Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors.
Modulators for heat shock proteins to treat Parkinson's and ALS diseases.
Compounds that enhance alpha-crystallin activity to prevent cataract formation.
Inhibitors of HSP90 and TRAP-1 for treating glioblastoma and brain tumors.
People of Plex Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
1 people
Sales and Marketing
1 people
Finance and Accounting
1 people
Scientific Team
1 people
Unlock access to complete
Funding Insights of Plex Pharmaceuticals
Investors in Plex Pharmaceuticals
Plex Pharmaceuticals has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include HHS, The Michael J. Fox Foundation and Collidion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Vision research is conducted to eliminate vision loss.
|
Locked | Locked | Locked |
Investor details for Plex Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Plex Pharmaceuticals
Investment portfolio details for Plex Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Plex Pharmaceuticals
Detailed financials for Plex Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Plex Pharmaceuticals Comparisons
Peer comparison for Plex Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Plex Pharmaceuticals
Plex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of Plex Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Plex Pharmaceuticals
Complete news archive for Plex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Plex Pharmaceuticals
Plex Pharmaceuticals was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Plex Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Plex Pharmaceuticals (formerly CalAsia Pharmaceuticals), an early stage biotechnology company is focussed on discovering small molecules for diseases caused by protein misfolding such as Amyotrophic lateral sclerosis (ALS), Parkinsons disease. Its technology platform combines functional fragment screening with X-ray crystallography co-crystallization guided by structure-based design approach to design and synthesize New Chemical Entities (NCEs) with drug-like properties. Its discovery programs include modulators of heat shock proteins (Hsp) and FK506 Binding Protein (FKBP) for the treatment of Parkinsons disease (PD) and Amyotrophic lateral sclerosis (ALS); small molecule for the treatment of Glioblastoma multiforme. The company also has discovery and preclinical programs for Zika, Dengue, and West nile virus.
Plex Pharmaceuticals's top competitors include Alector, Entrada Therapeutics and Annexon.
Plex Pharmaceuticals offers Neurodegenerative Drug Programs, Cataracts Treatment Molecules, and CNS Tumors Inhibitors.
Plex Pharmaceuticals has 5 investors. Key investors include HHS, The Michael J. Fox Foundation, Collidion, NIAID, and National Eye Institute.